Detailed Narrative
Cenexi Turnaround and Integration
Cenexi achieved a significant milestone by reaching EBITDA breakeven this quarter, reporting a positive EBITDA of ₹148 million (EUR 1 million) on revenues of EUR 50 million. This turnaround was driven by capacity debottlenecking, contract re-pricing to account for inflation, and workforce optimization. Management expects Cenexi to remain on a growth trajectory with an annualized revenue base of approximately EUR 200 million, supported by new high-speed lines and deeper operational integration with Gland's India operations.
US Market Resilience and Volume Growth
The US market remains Gland's primary growth engine, with revenue increasing 16% YoY to ₹8,290 million. While the segment faced pricing pressure of 5-6%, this was successfully offset by a 19% increase in volumes. The uptick is attributed to new GPO contracts for top products and the launch of 9 new molecules during the quarter. Management is focusing on internal efficiencies, such as increasing batch sizes and using larger capacity tanks, to maintain margins despite lower pricing.
Strategic Pivot to Complex CDMO
Gland is aggressively moving toward high-end innovation-led CDMO services. A key highlight is the securing of a new oncology CDMO contract expected to generate $25-30 million in annual revenue starting in late FY28. This project requires a dedicated ₹80 crore capex for a compounding area. The company is also expanding its pipeline into hormones, peptides, and biosimilars, moving beyond traditional B2B models to secure long-term revenue visibility.
Massive Capacity Expansion in Cartridges
The company is significantly scaling its cartridge fill and finish capacity from 40 million to 140 million units to capture the growing GLP-1 and insulin market. While the additional 100 million unit line is expected to be ready for exhibit batches by Q2 FY27, initial utilization is projected at a conservative 15-20 million units for FY27. Management emphasized that the lines are fungible, allowing them to fill vials and cartridges on the same equipment to mitigate underutilization risks.
Long-term Capex and Financial Health
Gland announced a ₹2,000 crore brownfield capex plan over the next five years, primarily targeting BFS (Blow-Fill-Seal) and ophthalmic lines where current capacity is nearly exhausted (80-90% utilization). Despite this heavy investment, the company maintains a strong balance sheet with ₹30,525 million in cash and equivalents. The investment strategy is disciplined, targeting a minimum 20% IRR and expected asset turns of 3x for the new high-value facilities.